Ihsan Hamdi Nijem

Title: Ihsan Hamdi Nijem: Innovator in Fixed Dose Combination Therapies

Introduction

Ihsan Hamdi Nijem is a notable inventor based in Brisbane, California. He has made significant contributions to the field of pharmaceuticals, particularly in the development of fixed dose combination therapies. His work has the potential to improve treatment options for patients requiring specific medications.

Latest Patents

Nijem holds a patent for a fixed dose combination of pertuzumab and trastuzumab, which is administered subcutaneously to patients. This invention, titled "Pertuzumab plus trastuzumab fixed dose combination," also includes the optional use of recombinant human hyaluronidase (rHuPH20). The patent encompasses the final efficacy and safety data from the FeDeriCa clinical trial, as well as the United States Prescribing Information (USPI) and primary analysis of the PHranceSCa clinical trial. He has 1 patent to his name.

Career Highlights

Throughout his career, Nijem has worked with prominent companies in the pharmaceutical industry, including Genentech, Inc. and Hoffmann-La Roche Inc. His experience in these organizations has contributed to his expertise in drug development and innovation.

Collaborations

Nijem has collaborated with several professionals in his field, including Tanja Badovinac-Crnjevic and Yu Chien Fredriksson. These collaborations have likely enhanced his research and development efforts.

Conclusion

Ihsan Hamdi Nijem is a distinguished inventor whose work in fixed dose combination therapies has the potential to significantly impact patient care. His contributions to the pharmaceutical industry are noteworthy and reflect his commitment to innovation.